VentureBeat

A2 Bio Publishes Key Preclinical Findings Demonstrating Potential of Its Highly Selective Tmod™ Cell Therapy Platform to Revolutionize the Treatment of Solid Tumors in Select ...

A2 Biotherapeutics, Inc. (“A2 Bio”), a biotechnology company focused on the treatment of solid tumors, announced today that key preclinical data related to its proprietary Tmod™ cell therapy platform ...
Business Wire

A2 Bio Highlights Progress of Tmod™ CAR T-Cell Clinical Programs During 2024 Annual Meeting of the Society for Immunotherapy of Cancer

HOUSTON--(BUSINESS WIRE)--A2 Biotherapeutics, Inc. (A2 Bio), a clinical-stage cell therapy company developing first-in-class logic-gated cell therapies to selectively target tumor cells and protect ...
Business Wire

A2 Bio to Present at ASCO-GI 2022 on Use of Next Generation Sequencing (NGS) to Identify GI Cancer Patients for Future Tmod™ CAR T Therapy

AGOURA HILLS, Calif.--(BUSINESS WIRE)--A2 Biotherapeutics, Inc. (“A2 Bio”) is a biotechnology company focused on the development of a first-in-class, logic-gated Tmod™ CAR T cell therapy platform to ...